Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicia Cosman

Showing results (51-60 of 117) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Endocrinology and Metabolism|May 12, 2015
Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on AlendronateFelicia Cosman, Jeri W Nieves, Marsha Zion, et al.
Bone|January 10, 2016
Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged womenJeri W Nieves, Jamie A Ruffing, Marsha Zion, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 10, 2016
Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk FactorsFelicia Cosman, Gary Hattersley, Ming-Yi Hu, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 4, 2004
The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]Etah S Kurland, Samantha L Heller, Beverly Diamond, et al.
Nutrition & Metabolism|August 9, 2007
The influence of lifestyle, menstrual function and oral contraceptive use on bone mass and size in female military cadetsJamie A Ruffing, Jeri W Nieves, Marsha Zion, et al.
Endocrinology|June 16, 2007
The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J miceSara Johnston, Sharon Andrews, Victor Shen, et al.
Bone|April 25, 2020
Loading modality and age influence teriparatide-induced bone formation in the human femoral neckAmanda M Rooney, Mathias P G Bostrom, David W Dempster, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 13, 2014
Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension studyRichard Eastell, Steven Boonen, Felicia Cosman, et al.
Bone|October 26, 2018
Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated womenFelicia Cosman, Jeri W Nieves, Catherine Roimisher, et al.
Bone|January 29, 2022
Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neckAmanda M Rooney, David W Dempster, Jeri W Nieves, et al.
Pageof 12

Showing results (51-60 of 117) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Endocrinology and Metabolism|May 12, 2015
Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on AlendronateFelicia Cosman, Jeri W Nieves, Marsha Zion, et al.
Bone|January 10, 2016
Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged womenJeri W Nieves, Jamie A Ruffing, Marsha Zion, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 10, 2016
Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk FactorsFelicia Cosman, Gary Hattersley, Ming-Yi Hu, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 4, 2004
The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]Etah S Kurland, Samantha L Heller, Beverly Diamond, et al.
Nutrition & Metabolism|August 9, 2007
The influence of lifestyle, menstrual function and oral contraceptive use on bone mass and size in female military cadetsJamie A Ruffing, Jeri W Nieves, Marsha Zion, et al.
Endocrinology|June 16, 2007
The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J miceSara Johnston, Sharon Andrews, Victor Shen, et al.
Bone|April 25, 2020
Loading modality and age influence teriparatide-induced bone formation in the human femoral neckAmanda M Rooney, Mathias P G Bostrom, David W Dempster, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 13, 2014
Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension studyRichard Eastell, Steven Boonen, Felicia Cosman, et al.
Bone|October 26, 2018
Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated womenFelicia Cosman, Jeri W Nieves, Catherine Roimisher, et al.
Bone|January 29, 2022
Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neckAmanda M Rooney, David W Dempster, Jeri W Nieves, et al.
Pageof 12